| Outcome | Injectable MTE subgroup | Oral MTE subgroup | Interaction P value |
|---|
| No. of studies | Estimate (95% CI) | I2 | No. of studies | Estimate (95% CI) | I2 |
|---|
| Response to treatment | 12 | POR 2.02 (1.58–2.58) | 0% | 2 | POR 1.94 (1.04–3.60) | 0% | 0.90 |
| Performance status | 7 | POR 2.94 (1.99–4.34) | 0% | 1 | POR 4.31 (1.89–9.84) | 0% | 0.41 |
| Leukopenia | 12 | RR 0.68 (0.57–0.82) | 42% | 3 | RR 0.57 (0.36–0.90) | 44% | 0.48 |
| Thrombocytopenia | 11 | RR 0.67 (0.49–0.93) | 33% | 2 | RR 0.42 (0.11–1.59) | 69% | 0.50 |
| Nausea/vomiting | 9 | RR 0.82 (0.71–0.94) | 0% | 2 | RR 0.47 (0.29–0.78) | 0% | 0.04 |
| Hepatic injury | 9 | RR 0.83 (0.62–1.12) | 19% | 2 | RR 0.61 (0.39–0.95) | 0% | 0.25 |
- Note: Subgroup analysis was unavailable for anemia, diarrhea, constipation, kidney injury, peripheral neurotoxicity, and oral mucosal lesions because all trials that assessed these outcomes used injectable Marsdenia tenacissima extract
- Abbreviations: MTE Marsdenia tenacissima extract; POR proportional odds ratio; RR risk ratio; CI confidence interval
